311 related articles for article (PubMed ID: 23451981)
1. Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.
Gombar VK; Hall SD
J Chem Inf Model; 2013 Apr; 53(4):948-57. PubMed ID: 23451981
[TBL] [Abstract][Full Text] [Related]
2. Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Gilibili RR; Bhamidipati RK; Mullangi R; Srinivas NR
J Pharm Pharm Sci; 2015; 18(3):434-48. PubMed ID: 26517136
[TBL] [Abstract][Full Text] [Related]
3. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods.
Yap CW; Li ZR; Chen YZ
J Mol Graph Model; 2006 Mar; 24(5):383-95. PubMed ID: 16290201
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
6. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Wang X; Zhang D; Xu W; Liu H; Wang W
Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
9. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
10. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
Berellini G; Springer C; Waters NJ; Lombardo F
J Med Chem; 2009 Jul; 52(14):4488-95. PubMed ID: 19603833
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-pharmacokinetic relationship modelling: apparent volume of distribution.
Ghafourian T; Barzegar-Jalali M; Hakimiha N; Cronin MT
J Pharm Pharmacol; 2004 Mar; 56(3):339-50. PubMed ID: 15025859
[TBL] [Abstract][Full Text] [Related]
13. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
14. In Silico Prediction of Human Intravenous Pharmacokinetic Parameters with Improved Accuracy.
Wang Y; Liu H; Fan Y; Chen X; Yang Y; Zhu L; Zhao J; Chen Y; Zhang Y
J Chem Inf Model; 2019 Sep; 59(9):3968-3980. PubMed ID: 31403793
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
16. In Silico Models of Human PK Parameters. Prediction of Volume of Distribution Using an Extensive Data Set and a Reduced Number of Parameters.
Lombardo F; Bentzien J; Berellini G; Muegge I
J Pharm Sci; 2021 Jan; 110(1):500-509. PubMed ID: 32891631
[TBL] [Abstract][Full Text] [Related]
17. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
[TBL] [Abstract][Full Text] [Related]
18. Prediction of human volume of distribution values for drugs using linear and nonlinear quantitative structure pharmacokinetic relationship models.
Louis B; Agrawal VK
Interdiscip Sci; 2014 Mar; 6(1):71-83. PubMed ID: 24464707
[TBL] [Abstract][Full Text] [Related]
19. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.
Bazin-Redureau M; Pepin S; Hong G; Debray M; Scherrmann JM
Toxicol Appl Pharmacol; 1998 Jun; 150(2):295-300. PubMed ID: 9653060
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
